Clinical Trial News and Research

RSS

Scientists discover family of chemical compounds that could prevent malaria

A international team led by scientists from the Genomics Institute of the Novartis Research Foundation (GNF) and The Scripps Research Institute has discovered a family of chemical compounds that could lead to a new generation of antimalarial drugs capable of not only alleviating symptoms but also preventing the deadly disease.

17 Nov 2011

EC approves Pfizer's Vyndaqel to treat Transthyretin Familial Amyloid Polyneuropathy

Pfizer announced today that the European Commission has approved Vyndaqel (tafamidis) for the treatment of Transthyretin Familial Amyloid Polyneuropathy (TTR-FAP) in adult patients with stage 1 symptomatic polyneuropathy.

17 Nov 2011

Hemoglobin levels, blood pressure and male gender linked to higher risk of silent strokes in SCA children

Factors such as low hemoglobin levels, increased systolic blood pressure, and male gender are linked to a higher risk of silent cerebral infarcts (SCIs), or silent strokes, in children with sickle cell anemia (SCA), according to results from a large, first-of-its-kind study published online today in Blood, the Journal of the American Society of Hematology (ASH).

17 Nov 2011

Biothera completes enrollment in Imprime PGG Phase II combination study on NSCLC

EBiothera's Phase II non-small cell lung cancer (NSCLC) clinical trial evaluating Imprime PGG administered in combination with cetuximab (Erbitux), carboplatin and paclitaxel has met its goal of 90 patients and is fully enrolled, the company announced today.

17 Nov 2011

Stem cell therapy for heart failure: two studies two successes

The Center for Disease Control and Prevention says that heart failure affects nearly 6 million Americans leading to considerable risk of death, diminished quality of like and recurrent hospitalizations. Heart failure occurs when the heart can no longer pump enough blood to the rest of the body. The most common cause of heart failure is coronary artery disease, which narrows the small blood vessels that supply blood and oxygen to the heart.

17 Nov 2011

UTHealth study: Heart attack patients who call 911 are sicker

Cardiologists are quick to point to statistics showing that the "door-to-balloon" treatment time for heart attack patients has dropped significantly in the past few years. But a retrospective study reveals that those who call 911 are most likely to have suffered a severe heart attack and despite receiving treatment quickly, they are still dying at unacceptable rates, say researchers at The University of Texas Health Science Center at Houston.

17 Nov 2011

Aurora kinase inhibitor may treat neuroendocrine prostate cancer

An international team of researchers led by clinicians at Weill Cornell Medical College have discovered a genetic Achilles' heel in an aggressive type of prostate cancer -- a vulnerability they say can be attacked by a targeted drug that is already in clinical trials to treat other types of cancers.

17 Nov 2011

Supervised exercise more effective than stenting or medication for PAD

Supervised exercise was shown to be more effective than stenting or medication for improved walking ability in patients with peripheral artery disease. The findings from a national study were reported today at the 2011 American Heart Association Scientific Sessions meeting.

17 Nov 2011

New 2-DG-ABT combination cancer therapy triggers apoptosis

Researchers at the University of California, San Diego School of Medicine and Kyushu University Medical School say a novel combination of a specific sugar molecule with a pair of cell-killing drugs prompts a wide variety of cancer cell types to kill themselves, a process called apoptosis or programmed cell death.

17 Nov 2011

Bionovo initiates Menerba Phase 3 trial in menopausal hot flashes

Bionovo, Inc., a pharmaceutical company focused on the discovery and development of safe and effective treatments for women's health and cancer, today announced that the first patient has now been randomized and will begin dosing in the Phase 3 pivotal clinical trial evaluating the safety and efficacy of two doses of Menerba (MF101) among a cohort of postmenopausal women for the treatment of menopausal hot flashes.

17 Nov 2011

Incyte receives FDA approval for Jakafi to treat intermediate or high-risk MF

Incyte Corporation today announced that the U.S. Food and Drug Administration (FDA) has granted marketing approval for Jakafi (ruxolitinib) for the treatment of patients with intermediate or high-risk myelofibrosis (MF), including primary MF, post-polycythemia vera MF and post-essential thrombocythemia MF.

17 Nov 2011

First clinical trial of dapivirine-maraviroc ring to treat HIV in women

In the first clinical trial of a vaginal ring combining two antiretroviral (ARV) drugs, researchers from the Microbicide Trials Network (MTN) are collaborating with the International Partnership for Microbicides (IPM) to evaluate whether the ring is safe for use in women.

16 Nov 2011

NIAID's ACTG and TB Alliance partner to complete moxifloxacin Phase III trial

The TB Alliance announces the launch of a collaboration with the National Institute of Allergy and Infectious Diseases' (NIAID) AIDS Clinical Trial Group (ACTG) to conduct and help complete a Phase III clinical trial testing potentially faster-acting tuberculosis (TB) treatments.

16 Nov 2011

Researchers to begin drug development projects for rare and neglected diseases

Researchers will begin drug development projects for rare and neglected diseases that include potential treatments for a musculoskeletal disorder, a cognitive dysfunction disorder, a virus that affects the central nervous system of newborns, a parasitic worm infection, a form of muscular dystrophy and a rare lung disease.

16 Nov 2011

Evacetrapib drug may increase HDL-C and decrease LDL-C levels

Among patients with sub-optimal low-density lipoprotein cholesterol (LDL-C) or high-density lipoprotein cholesterol (HDL-C) levels, use of the drug evacetrapib alone or in combination with statin medications was associated with significant increases in HDL-C levels and decreases in LDL-C levels, according to a study appearing in the November 16 issue of JAMA, a theme issue on cardiovascular disease.

16 Nov 2011

Alnylam announces new data from ALN-TTR01 Phase I trial on TTR-mediated amyloidosis

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today that it will present new data from its ALN-TTR program at the VIIIth International Symposium on Familial Amyloidotic Polyneuropathy being held in Kumamoto, Japan from November 20-22, 2011.

15 Nov 2011

ProFibrix Fibrocaps effectively reduces bleeding in liver resection surgery

ProFibrix B.V., a leader in the development of innovative products for hemostasis, today announced that its multicenter Phase II clinical trial with Fibrocaps in liver resection surgery resulted in a highly statistically significant 50% reduction in mean time to hemostasis (TTH) compared to active control.

15 Nov 2011

Midatech receives Swissmedic approval to start trial of insulin-coated gold nanoparticle

Midatech Ltd., a global leader in the design, development, synthesis and manufacture of nanomedicines, announced today it has received Swissmedic approval to start the First-in-Human clinical trial with insulin-coated gold nanoparticles, which will be coordinated through its Swiss subsidiary PharMida AG.

15 Nov 2011

InVivo Therapeutics reports net income of $3,067,000 for third quarter 2011

InVivo Therapeutics Holdings Corp., a developer of groundbreaking technologies for the treatment of spinal cord injuries (SCI), today reported financial results for the three and nine months ended September 30, 2011 and provided a business update.

15 Nov 2011

Positive long-term data from Abbott's ABSORB drug eluting BVS trial on CAD

Abbott today announced positive long-term data from the two-stage ABSORB trial, which is evaluating the ABSORB drug eluting bioresorbable vascular scaffold (BVS) for the treatment of coronary artery disease.

15 Nov 2011